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Background: The role of respiratory viruses in cystic ﬁbrosis (CF) exacerbations is incompletely understood.
Methods: Cross-sectional study of CF children with a pulmonary exacerbation. Mid-turbinate swabs were tested by a direct immunoﬂuorescent
antibody assay and a multiplex PCR panel (ResPlex II v2.0, Qiagen). Resplex II was also applied to sputum or throat swab samples. Pulmonary
function tests and quality of life and severity scores were recorded. Sputum cell counts, bacterial density and cytokines were measured.
Results: 26/43 (60.5%) subjects tested positive for at least one respiratory virus by any diagnostic method applied to any sample type. Virus-
positive patients were younger (p=0.047), more likely to be male (p=0.029), and had higher CF clinical severity (p=0.041) and lower quality of
life (physical) scores (p=0.023) but similar IL-8, neutrophil percentage and elastase levels.
Conclusions: Compared to non-viral exacerbations, viral-related exacerbations were associated with worse severity and quality of life scores but
similar pulmonary inﬂammation.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pulmonary exacerbations; Respiratory viruses; Molecular diagnosis1. Introduction
Cystic fibrosis (CF) affects over 60,000 patients worldwide.
Bacterial infections are the main cause of recurrent pulmonary
exacerbations leading to progressive lung damage with less known
about the role of viral respiratory tract infections [1–3]. The true
impact of respiratory viruses in CF may have been previously
underestimated as the majority of previous studies [4,5] used viral
culture and/or immunofluorescence techniques which are relatively
insensitive and restricted in breadth for viral detection [1,2]. To
date, published reports of respiratory viral infections in children
with CF have primarily focused on the proportion of pulmonary⁎ Corresponding author. Tel.: +1 416 813 7654x3530; fax: +1 416 813 8404.
E-mail address: dat.tran@sickkids.ca (D. Tran).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.04.006exacerbations associated with viruses [1,4–8]. The relationship
between severity of these exacerbations and infection status with
respiratory viruses has not been assessed. The extent to which
these complications are mediated by direct viral effects or via
potentiation of bacterial colonization and infection is unclear [5].
The pulmonary manifestations of CF involve both neutrophil-
dominated airway inflammation and chronic bacterial infec-
tion. Although the temporal relationship between infection
and inflammation remains unclear in early disease, later in
disease there is a self-perpetuating cycle of airway obstruction,
chronic bacterial infection and vigorous inflammation resulting in
structural damage to the airway [9–11]. Less is currently known
about the contribution from viral infections. A better understand-
ing of the host inflammatory response following respiratory viral
infections may minimize the use of prolonged antibiotic therapy.by Elsevier B.V. All rights reserved.
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proportion of CF pulmonary exacerbations associated with a
respiratory viral infection, as detected by conventional diagnostics
and a commercially available multiplex molecular diagnostic
assay. Our secondary objectives were to determine the clinical
severity and pulmonary inflammation due to exacerbations
associated with viral infections.
2. Materials and methods
2.1. Participants
From November 1, 2009 to March 31, 2010, we conducted
an observational, cross-sectional study of children with CF
seen in the setting of a pulmonary exacerbation. Patients were
recruited from the respiratory medicine clinic at The Hospital
for Sick Children, a large pediatric referral center that cares for
approximately 280 CF patients. We enrolled all CF patients who
met the following inclusion criteria: ageb18 years; and clinical
presentation consistent with a pulmonary exacerbation, defined
as any of the following clinical symptoms: change in sputum
production, increased cough or dyspnea, alone or in combination
with temperature above 38 °C, and/or change in respiratory status
(tachypnea, indrawing, wheezing or crackles) reported by the
attending team. Informed consent (and assent from child as
appropriate) was obtained from all participants and ethics approval
was obtained from the Research Ethics Board at The Hospital for
Sick Children. Exclusion criteria included lack of consent and
insufficient command of English or absence of translator.
2.2. Collection of clinical information and specimens
Information on patient demographics and CF-relevant
baseline characteristics such as CF-related comorbidities and
bacterial colonization were abstracted from health records.
The Cystic Fibrosis Questionnaire-Revised (CFQ-R ) [12] and
the Cystic Fibrosis Clinical Score (CFCS) [13] were prospectively
administered to participants through standardized interviews and
physical assessments. The CFCS is an acute clinical score, based
on signs and symptoms. It was chosen as a severity scale because
of its reliability and its ease of use [13]. Body mass index (BMI)
percentile was calculated for children≥2 years of age andweight-
for-recumbent length percentile for those under the age of 2 [14].
Mid-turbinate flocked swabs (Copan Diagnostics, Murrietta, CA),
collected from all enrolled patients, were placed into in 3 mL of
Universal Transport Medium (UTM-RT COPAN Diagnostics,
Murrieta, CA). In addition, children old enough to produce
sputum provided sputum samples while FLOQ COPAN throat
swabs (inoculated in UTM) were obtained from those unable to
produce sputum (refer to Fig. 1 for sample collection and testing).
2.3. Virology studies
Mid-turbinate specimens were examined by 1) direct fluores-
cent antigen assay (DFA) for 8 respiratory viruses (respira-
tory syncytial virus (RSV), influenza virus [A,B] (INFA/INFB),
parainfluenza [types 1–3] (PIV), adenovirus (ADV) (SimulFluor®,Millipore, Temecula, CA) and human metapneumovirus (hMPV)
(Diagnostic HYBRIDS, Athens, OH); 2) a nucleic acid
amplification-based assay (ResPlex II v2.0, Qiagen, Mississauga,
ON, Canada) for detection of 18 respiratory viruses (RSV [A, B],
coronaviruses [OC43, 229E, NL63, HKU1], rhinovirus (HRV),
cocksackie/echovirus, PIV [types 1–4], INFA, INFB, bocavirus,
ADV [B, E] and hMPV); and 3) reverse transcription poly-
merase chain reaction (RT-PCR) for specific identification of the
pandemic 2009 influenza A H1N1 (pH1N1) virus (Astra
influenza Screen and Type (Astra Diagnostics, Hamburg,
Germany or RT-PCR Kit 1.0, Astra Diagnostics, Hamburg,
Germany)). We also applied the ResPlex II v2.0 panel to FLOQ
COPAN throat swabs and Sputolysin (10.14 mg/ml, CALBIO-
CHEM)-treated sputum sample after ensuring that Sputolysin
would not affect the performance of the assay (Fig. 1). To evaluate
the potential interference of Sputolysin with the efficiency of
nucleic acid extraction and performance of the assay, we randomly
chose four known positive mid-turbinate samples (RSV B, PIV 1,
HRV/INFA and RSVA) from another study and divided them each
into two equal aliquots. The potential interference of Sputolysin
was tested on mid-turbinate swabs instead of sputum samples as
non Sputolysin-treated sputum samples would not enable appro-
priate nucleic acid extraction because of the sputum viscosity. We
mixed one aliquot with an equal volume of 10% Sputolysin in PBS
(phosphate buffered saline) and the other with an equal volume of
PBS alone. After incubation for 10 min at room temperature,
we extracted total nucleic acids from both aliquots with the
NucliSENS easyMAG (bioMerieux, St Laurent, QC, Canada )
followed by amplification with the Resplex II v2.0 assay [15]. A
patient was classified as being virus-positive if a respiratory virus
was detected in the mid-turbinate or throat or sputum sample by
any one of the three assays used (DFA, Resplex II v2.0 or RT-
PCR).
2.4. Bacteriologic confirmation and load assessment
Sputum samples underwent bacterial density analysis
for Pseudomonas aeruginosa, Staphylococcus aureus and
Haemophilus influenzae based on the predominant organism
isolated on the routine bacterial culture using previously
described methods [16].
2.5. Inflammatory markers and sputum neutrophil percentage
Levels of IL-8 and 26 additional inflammatory cytokines
(PDGF, Il-1 B, Il-1 RA, Il-2, Il-4, Il-5, Il-6, Il-7, Il-9, Il-10, Il-12, Il-
13, Il-15, Il-17, Eotaxin, FGF, G_CSF, GM_CSF, IFN_G, IP_10,
MCP_1, MIP_1A, MIP_1B, RANTES, TNF_alpha, VEGF) were
measured on Sputolysin-treated sputum samples using a com-
mercial multiplex bead-based assay (Bio-Plex Cytokine Assay,
Bio-Rad) [17,18]. The detection range for all cytokines was
0–32,000 pg/ml as per the manufacture guidelines [26]. Neutro-
phil elastase (NE) activity was measured using a modified
enzymatic assay based on NE cleavage of nitroanilide from
N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide and results were
reported in units/ml (1 unit=mmol/min). Lower limit of detection
was 0.006 units/ml [10]. Sputum neutrophil percentage is the
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Fig. 1. Flow diagram of the collection and processing of midturbinate swabs, sputum and throat-swab specimens.
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2.6. Lung function testing
Children old enough to perform spirometry had standard
spirometry done at enrollment and routinely at every visit. We
reported forced expiratory volume in 1 s (FEV1) as a percentage
of predicted value for sex and height using the equation of Corey
et al. [19]. We defined baseline FEV1 as the best FEV1 in the6 months prior to the current pulmonary exacerbation, and
exacerbation FEV1 as the FEV1 at the time of presentation with a
pulmonary exacerbation.
2.7. Statistical analyses
Standard descriptive and comparative statistics were used on
data categorized by viral infection status (virus-positive and
virus-negative patients). For normally-distributed continuous
variables (total bacterial densities and bacterial densities for
436 S. Asner et al. / Journal of Cystic Fibrosis 11 (2012) 433–439S. aureus, P. aeruginosa and H. influenzae), we calculated
means and analyzed differences between the comparator groups
using Student's t-test. For skewed data (age, obesity measures,
FEV1% predicted, CFSC and CFQ-R scores, IL-8 levels, sputum
neutrophil percentage and count, sputum neutrophil elastase), we
derived medians and used the Mann–Whitney method for
comparisons. The χ2 test or Fisher's exact test was used to
compare categorical variables between groups as appropriate.
Using standard formulae, we estimated the sensitivities and
specificities (with respective binomial 95% confidence intervals
(CI)) of mid-turbinate swabs, sputum samples and throat swabs for
virus detection relative to the combination of these sample types as
the reference standard. Differences in test performance were
calculated using McNemar's test. A p valueb0.05 was considered
statistically significant. Data were analyzed by SPSS statistical
software (version 16.0, SPSS Inc, Chicago, IL, USA).3. Results
3.1. Viral detection studies
A total of 112 CF patients were screened for inclusion in the
study between November 2009 and March 2010. Of these, 47
(42%) met eligibility criteria, 4 of whom (8.5%) declined
participation in the study. Among the 43 enrolled patients, 26
(60.5%) were classified as virus-positive: 25/26 (96.2%) from
mid-turbinate swabs and 6/26 (23.0%) from either sputum
samples or throat swabs by any one of the three assays used (8 by
DFA, 2 by RT-PCR and 26 by multiplex PCR). Of those 26
virus-positive subjects, 17 (65.4%) tested positive for one virus
and the remaining 9 (34.6%) for two or more viruses (all by
ResPlex II v2.0). From the 17 participants who tested positive for
only one respiratory virus, coxsackie/echovirus was the most
commonly identified pathogen (29.4%) (Table 1). RSV was
reported from all participants who tested positive for two viruses
(6/6) (Table 1).Table 1
Identified viruses among virus-positive subjects identified by any diagnostic
method applied to any sample (mid-turbinate swabs, throat swabs or sputum
samples).
Virus Single viral infection Viral co-infection
(n=17) (n=9)
Coxsackie/echovirus 5 (29.4) 4 (44.4)
Rhinovirus 3 (17.6) 3 (33.3)
RSV a A 2 (11.8) 4 (44.4)
RSV B 1 (5.9) 2 (22.2)
Parainfluenza 2 2 (11.8) 1 (11.1)
Parainfluenza 3 1 (5.9) 0
Adenovirus B 2 (11.8) 1 (11.1)
pH1N1 b 1 (5.9) 1 (11.1)
hMPV c 0 2 (22.2)
Coronavirus 0 4 (44.4)
a Respiratory syncytial virus.
b Pandemic 2009 influenza A H1N1.
c Human metapneumovirus.3.2. Patient characteristics and clinical status at the time of
pulmonary exacerbation
Virus-positive patients were significantly younger (p=0.047)
and more likely to be male (p=0.029) than virus-negative
patients. Also, they were significantly more likely to present with
fever (p=0.019) but not with upper respiratory tract infection
symptoms (p=0.941) (Table 2). There were no other significant
differences between the two groups. At the time of exacerba-
tion, virus-positive patients had significantly higher CF
clinical score (CFCS) (27 vs 24; p=0.041) and lower quality
of life (physical) CFQ-R score (53.4 vs 75.3; p=0.030)
(Table 3). When the patient's viral infection status was
determined without incorporating the positive rhinovirus and
coxsackie/echovirus results, the physical CFQ-R score of virus-
positive patients remained significantly lower (58.5 vs 194.5;
p=0.022). However, CFCS was no longer significantly different
between virus-positive and negative patients. Antibiotic use,
hospitalization requirements and mean percent predicted exacer-
bation FEV1 were not significantly different between the two
groups (Table 3).
3.3. Pulmonary inflammation
Bacterial densities were examined in sputum samples from
8/26 (30.8%) virus-positive and 7/17 (41.2%) virus-negative
patients. The mean total bacterial density observed in virus-
positive patients was two logs lower (albeit not statistically
significant) than that found in virus-negative patients (3.9×107
vs 1.8×10 9 CFU/mL; p=0.299). Virus-positive and negative
patients had similar IL-8, neutrophil percentage and neutrophil
elastase levels (Table 3). There was also no difference in the 26
additional cytokines levels between both groups (Supplementary
Table 1).
3.4. Comparison of viral detection in mid-turbinate swabs and
sputum or throat swab samples
A total of 21/43 (48.8%) patients had concomitant sputum
samples and 11/43 (25.6%) had concomitant throat swabs tested
for respiratory viruses by ResPlex II v2.0. Overall, the detection
rate of respiratory viruses using mid-turbinate swabs was similar to
that of throat swabs (7/11 vs 6/11) but higher than that of sputum
samples (11/21 vs 6/21) (Supplementary Table 2). For classifica-
tion of infection status based on detection of at least one respiratory
virus, mid-turbinate swabs had a 76% (16/21) concordance rate
with sputum samples (concordant pairs: 6 positive/positive, 10
negative/negative; discordant pairs: 5 positive/negative, 0 negative/
positive) and 72.7% (8/11) concordance rate with throat swabs
(concordant pairs: 5 positive/positive, 3 negative/negative; discor-
dant pairs: 2 positive/negative, 1 negative/positive). The sensitiv-
ities of mid-turbinate swabs and sputum samples relative to the
combination of mid-turbinate and/or sputum samples were
100.0% (95% CI, 67.9–100.0) and 54.5% (95% CI, 24.6–81.9)
respectively, while the specificities were both 100.0% (95% CI,
Table 2
Baseline characteristics of virus-positive and virus-negative patients.
Virus-positive Virus-negative p
value
(n=26) (n=17)
Month of exacerbation 0.775
– November 2009
– December 2009
– January 2010
– February 2010
9 (34.6) 7 (41.2)
6 (23.1) 2 (11.8)
8 (30.8) 5 (29.4)
3 (11.5) 3 (17.6)
Symptom duration at date of swab
– Mean (range)
– Median (IQR a)
7.5 (2–21) 12.3 (2–21) 0.066
6 (3–10) 14 (2.5–21) 0.290
Patient characteristics at enrollment
Age, y, median (IQR) 6.9 (3.8–13.5) 13 (6.5–15.4) 0.047
Male 14 (53.8) 4 (23.5) 0.029
Weight-for-recumbent length percentile
– Median (IQR) 50 (30–82.5) – –
BMI percentile
– Median (IQR) 24 (5–50) 25 (10–50) 0.474
Homozygous DF508 6 (23.1) 9 (52.9) 0.588
Baseline predicted FEV1 17 (65.4) 15 (88.2) 0.268
– Median (IQR) 68 (57.5–87) 85 (63–94) 0.243
Upper respiratory tract infection 11 (42.3) 7 (41.2) 0.941
Fever 12 (46.2) 2 (11.8) 0.019
Comorbidities
Pancreatic insufficiency 17 (65.4) 13 (76.5) 1.0
CF-related diabetes 2 (7.7) 1 (5.9) 1.0
ABPA b 4 (15.4) 5 (29.4) 0.462
Bacterial colonization at enrollment
Throat swabs (n=16) 12 4
– Staphylococcus aureus 4 (33.3) 1 (25) 0.755
– Pseudomonas aeruginosa – – –
Sputum samples (n=27) 14 13
– Staphyloccocus aureus 8 (57.1) 9 (69.2) 0.340
– Pseudomonas aeruginosa 2 (14.3) 2 (15.4) 1
Influenza vaccination status
Received seasonal influenza vaccine 6 (23.1) 6 (35.3) 0.667
Received pH1N1 vaccine 9 (34.6) 11 (64.7) 0.291
Note. Data are n (%) unless otherwise indicated.
a Interquartile range (25th–75th percentile).
b Allergic bronchopulmonary aspergillosis.
Table 3
Clinical status of patients with and without viruses at pulmonary exacerbation.
Virus-positive Virus-negative p
value
(n=26) (n=17)
Predicted FEV1 a 17 (65.4) 15 (88.2) 0.447
– Median (IQR b) 48 (39.5–64.8) 60 (44–79) 0.213
Received antibiotics 18 (69.2) 11 (64.7) 0.335
Hospitalized 9 (34.6) 5 (29.4) 0.504
CFCS c 25 (96.1) 16 (94.1) 0.234
– Mean (range)
– Median (IQR)
27.2 (19–39) 23.7 (17–41) 0.061
27 (18–30) 24 (18–27) 0.041
CFQ-R d (physical) 18 (69.2) 15 (88.2) 0.405
– Mean (range)
– Median (IQR)
58.3 (33.3–78.2)
53.4 (0–100)
79.2 (61.1–91.7)
75.3 (11.1–100)
0.028
0.030
Sputum IL-8 11 (42.3) 6 (35.3) 0.386
– Median (IQR), pg/ml 1785.8
(779–2936.9)
1403
(336–2448.5)
0.615
Sputum neutrophil percentage 11 (42.3) 5 (29.4) 0.553
– Median (IQR) 99.5 (99.3–99.9) 99. 3 (99–99.5) 0.402
Sputum neutrophil count 11 (42.3) 5 (29.4) 0.553
– Median (IQR), μ/ml 398 (397–399) 398 (396–399.5) 0.863
Sputum neutrophil elastase 11 (42.3) 6 (35.3) 0.386
– Median (IQR), μ/ml 0.2 (0.1–0.3) 0.3 (0.1–0.5) 0.421
Sputum total bacterial density 8 (30.8) 7 (41.2) 0.449
– Mean (SD) e, colony forming
units/mL
3.9×107
(6.9×107)
1.8×109
(4.5×109)
0.299
Staphylococcus aureus
bacterial density
5 (19.2) 5 (29.4) 0.350
– Mean (SD), colony forming
units/mL
1.3×107
(2.6×107)
5.9×107
(8.0×107)
0.249
Pseudomonas aeruginosa
bacterial density
2 (7.7) 2 (11.8) 0.261
– Mean (SD), colony forming
units/mL
1.3×108
(1.0×108)
6.0×109
(8.5×109)
0.431
Haemophilus influenzae
bacterial density
1 (3.8) – –
Note. Data are n (%) unless otherwise indicated. * No observations.
a Forced expiratory volume in one second at exacerbation.
b Interquartile range (25th–75th percentile).
c Cystic ﬁbrosis clinical score.
d Cystic Fibrosis Questionnaire-Revised.
e Standard deviation.
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sensitive than sputum samples (p=0.0625). We did not calculate
sensitivities and specificities for the mid-turbinate/throat swabs
paired samples due to limited numbers.
4. Discussion
The proportion of virus-associated exacerbations document-
ed in our study is similar to those demonstrated in recent studies
using molecular-based techniques (60.0% and 49.8%) [20] and
significantly higher than those found in prior studies using
conventional diagnostic methods (b15%) [4,5]. These discrep-
ancies can be attributed to the higher sensitivity and broader
range of virus detection afforded by molecular-based methodsleading to a better estimation of the true prevalence of respiratory
viruses in CF exacerbations.
Rhinoviruses have been reported as major pathogens in CF
exacerbations [1,22] with detection rates reaching 87% from
samples collected both from exacerbations and routine visits [20].
Ours and another study [1] reported similar rates of rhinovirus
detection (17.6% vs 15.9%) from samples collected during
exacerbation. Rhinovirus and coxsackie/echovirus comprised
half of our identified viruses. Given the ResPlex II v2.0 assay's
suboptimal performance in distinguishing rhinovirus from
coxsackie/echovirus, our true rate of rhinovirus detection might
have been even higher [21].
Our study documented a low proportion of pH1N1 (5.3%)
even though it was conducted during the larger second wave of
the 2009 influenza with a modest pH1N1 vaccine uptake
rate (46.5%). Another study [1] conducted during a typical
influenza season reported higher influenza A and B detection
rates (25%) despite a high influenza vaccination uptake of 70%.
438 S. Asner et al. / Journal of Cystic Fibrosis 11 (2012) 433–439These discrepancies may be related to the perfect matching of
the pH1N1 vaccine to the circulating influenza viruses during
our study period.
Compared to another study [1], our rate of viral coinfection
was significantly higher (34.6% vs 4.3%). These discrepancies
can be attributed to the broader range of virus detection afforded
by the ResPlex II v2.0 assay compared to other molecular-based
methods used in this study (detection of 18 viruses vs 9 viruses)
[1]. Multiplex assays permit the improved identification of cases
of infection with multiple agents although the impact of multiple
viral infections on the clinical course of disease is at present
unknown and worthy of further study [21].
To our knowledge, this is the first study to assess the severity of
viral-associated pulmonary exacerbations and their impact on
quality of life. Virus-positive subjects had significantly higher
severity and lower quality of life scores. Our ability to detect a
difference in severity scores between the two groups but not
other metrics of pulmonary exacerbation severity may reflect the
increased statistical power afforded by the quantitative nature of
the severity and quality of life scores. Another study [22]
suggested that children in whom a virus other than rhinovirus or
coxsackie/echovirus was identified had a significantly greater
decline in FEV1 from baseline compared to children with a
rhinovirus infection. However, our repeat analyses after excluding
the rhinovirus and coxsackie/echovirus-positive patients did
not change the above findings other than the difference in the
CFCS which became insignificant. This might reflect a decreased
discriminative ability of CFCS compared to the CFQ-R, the
underpowered sample size after excluding rhinovirus and cox-
sackie/echovirus-positive patients, and/or a biased estimate result-
ing from missing CFQ-R data.
Several studies have correlated repeated bacterial infections in
CF patients with increased airway inflammation, whereas the
pathophysiology of virus-induced CF exacerbation remains
unclear [9–11]. In our study, levels of sputum IL-8, neutrophil
percentage and neutrophil elastase were within ranges of published
data [9,17] whereas sputum neutrophil cell counts were lower than
what have been described in the literature [9,17]. Our study
included outpatients with milder exacerbations and consisted of a
younger patient-population which may have resulted in a milder
degree of airway inflammation and therefore in lower sputum
neutrophil counts. We also found levels of inflammatory cytokines
in both groups to be similar but reported a two-log lower mean
total bacterial density in virus-positive subjects compared to the
virus-negative ones (albeit not significant), likely due to the
younger age of virus-positive subjects. A recent study [23]
reported a trend toward lower cytokine production in CF airway
epithelial cells following viral infection. Whether respiratory
viruses themselves or by interaction with bacteria induce the
observed inflammation remains controversial and requires further
investigation.
The data available for the optimal method for respiratory viral
detection is limited and controversial [1]. Our study reported a
higher rate of viral detection with mid-turbinate swabs than with
sputum samples in contrast with another recent study which
reported higher concordance rates (87% for rhinoviruses detection
and 92% for other virus types) [24]. The difference in timing ofsampling between this study (23% of samples collected during
exacerbation) and ours (100% during exacerbation) might
have contributed to these observed differences. A larger study
comparing test performance characteristics of paired upper
airway and sputum samples collected during exacerbations
would provide insights into the above findings.
Our study has several limitations. The observational design
limits our ability to exclude the effect of measured or unmeasured
covariates in our analysis. Despite the central importance of
pulmonary exacerbations as an outcome measure in CF clinical
trials, no standardized definition of pulmonary exacerbation that
includes children under the age of 6 has been validated. In using a
broader definition of pulmonary exacerbation which includes
children managed as outpatients, our sample may have included
more patients withmild exacerbations than other studies. However,
the proportion of hospitalized patients with viral infection in our
study (64%) was similar to that of outpatients (58%). Likewise,
there are no generally accepted severity scores for pulmonary
exacerbations that apply to younger children, including the
CFQ-R, a validated and widely used patient-reported outcome.
Despite its validation against PFTs as the gold standard, the CFCS
has been infrequently used in clinical trials. This highlights the
need for further evaluation of its applicability in clinical studies.
Our small sample size did not permit subgroup analyses according
to individual viruses. Finally, we did not have data on viral
infection status in CF children not experiencing an exacerbation as
a comparator to strengthen the association between the exacerba-
tion and viral infections. Compared to other viruses such as RSV,
rhinoviruses can shed for a prolonged period (N3 weeks vs
b1 week) [25] and may have been acquired before the exacerba-
tion. However, virus-positive subjects were more likely to present
with fever upon exacerbation.
In conclusion, respiratory viruses, especially coxsackie/
echovirus and rhinovirus are frequently associated with
pulmonary exacerbations in pediatric CF patients. Systematic
detection of respiratory viruses by molecular techniques using
mid-turbinate swabs should occur in the setting of a pulmonary
exacerbation. The relative contribution of repeated respiratory viral
infections in young children to pulmonary inflammation and
continuing decline in lung function seen from an early age is not
known. A longitudinal study which documents the decline in
FEV1 over time and comprehensively evaluates patients for both
viral and bacterial infections during exacerbations might help to
clarify the contribution of respiratory viruses to progressive lung
damage.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.04.006.
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